Fundraising FoxDeerfield Management Company — 2017 Investments
4 investments dated 2017 · listed companies and verified rows first · show all
Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.
BiotechBedford, US
Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)
BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)
Co-investors5AM VenturesARCH Venture PartnersOUP (Osage University Partners)AlexandriaFidelity InvestmentsHBM Healthcare Investments+5 more
Endologix develops medical devices and therapies for treating vascular disease, focusing on interventions such as EVAR (endovascular aneurysm repair) procedures.
HardwareHealthtechMedical DevicesSanta Rosa, US
Michael V. Chobotov(Executive Officer)inSHARI L. O'QUINN(Executive Officer)inMichael R. Kramer(Executive Officer)KIMBERLEY ELTING(Executive Officer)CHRISTOPHER CHAVEZ(Executive Officer, Director)VIVEK K. JAYARAMAN(Executive Officer)in
Co-investors415 CapitalKaiser Permanente VenturesNew Enterprise Associates (NEA)SR One Capital Management
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.